Matteo Lambertini, MD PhD
@matteolambe
Followers
16K
Following
24K
Media
1K
Statuses
11K
Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Chair of @myESMO YOC. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia.
Joined December 2012
Presented today at #SABCS23 and published in @JAMA_current results of our study showing the feasibility and safety of #pregnancy after #BreastCancer in young #BRCA carriers. @OncoAlert @SABCSSanAntonio @AACR @UniGenova @SanMartino_Ge #bcsm. Link here:.
18
66
221
Finally out in @NEJM results from #POSITIVE trial showing that temporary interruption of #EndocrineTherapy to attempt #pregnancy is safe in #BreastCancer patients: this is wonderful news…super congrats @AnnPartridgeMD @etop_ibcsg et al! @OncoAlert #bcsm.
8
189
516
Honored and excited to share our large #metanalysis presented at #SABCS20 now published in @ASCO_pubs #JCO providing solid and reassuring evidence on fetal and maternal safety of #pregnancy after prior #BreastCancer history. @OncoAlert #SurvOnc #bcsm.Link:
21
137
419
From January 1, 2023 I have been appointed as Chair of @myESMO Young Oncologists Committee #ESMOYOC. a big THANK YOU to all the people that have helped me to achieve this position and to those that will contribute in the next 2 years to succeed in our mission!.@OncoAlert
48
24
398
This person is a young oncologist. This person is Italian. This person is the discussant at the #ASCO22 plenary session. @ChiaraCrem1 is the Queen of Italy 🇮🇹🔥❤️🔝💪🤩. #ItalianPride @OncoAlert @ASCO @ASCOPost @ConquerCancerFd @JCO_ASCO @AIOMtweet
14
25
339
. the second best day of my life. benvenuto Ruggero. Giulia, Agnese and I are so excited to welcome you in our family!!! 💙👨👩👧👦🎉. #RuggeroLambertini #welcome #FamilyIsGrowing #FamilyFirst #proudDaddy #papàbis #doubledad #6thSeptember2021 #OspedaleSanMartino #UNIGE #UNIGEnonsiferma
39
3
304
Finally out the #ASCO23 Educational Book with our contribution on managing menopausal symptoms, #fertility preservation & bone health in #BreastCancer patients receiving #EndocrineTherapy.Link for free download:. @ASCO @kristinrojasmd @Lucarecco @OncoAlert
9
75
272
Finally the controversy on #carboplatin use as part of neoadjuvant #chemotherapy in triple-negative #BreastCancer patients is over: super congrats to our Indian colleagues for running such an important academic trial!. @OncoAlert @SABCSSanAntonio @Poggio_Fra #bcsm #SABCS22
6
81
266
February 1, 2022 .Finally, super excited and honored to become Associate Professor in medical oncology at @UniGenova @SanMartino_Ge. many many thanks to all the people that have supported me over the past years. ready for this new challenge !. @OncoAlert #UNIGEnonsiferma #UNIGE
32
8
257
Finally out in @ASCO_pubs our #ASCO19 data: strong evidence to state that #pregnancy after #BreastCancer is safe in patients with germline #BRCA mutations and should not be discouraged.@ASCO #OncoAlert #JCO #bcsm #UNIGEnonsiferma @UniGenova @SanMartino_Ge.
18
95
228
Finally it’s time for the #DESTINYbreast04 trial at #ASCO22 plenary session: so excited to be in the 2nd row of this big room to see such unprecedented results in the #BreastCancer field. this will remain one of the most important moment in the history of this disease.@OncoAlert
3
44
214
Updated results from #MONARCH3 at #ESMO22: addition of #abemaciclib to an aromatase inhibitor improves overall survival in endocrine sensitive advanced #bcsm (not significant at this interim analysis but to me clinically relevant: mOS=67 months, >1y gain).@OncoAlert @myESMO
7
74
211
Excited to share our @TheLancetOncol review on how to manage side-effects of adjuvant #EndocrineTherapy in #BreastCancer patients. @AliceFranzoi @ElisaAgostinett @MartaPerachino @E_de_Azambuja @delmastro_lucia @inesvazluis @YoungStrongDFCI @OncoAlert #bcsm.
10
69
210
So excited to see in person these data. no comments needed!!!! .#ESMO21 #PresidentialSession @myESMO @OncoAlert @JavierCortesMD #DESTINYbreast03
5
52
210
A few hours before #ASCO22 plenary session, out in @NEJM results of #destinyBreast04 trial showing impressive survival improvement (doubling of PFS with HR 0.51 and major OS gain) with #TrastuzumabDeruxtecan in #HER2-low advanced #BreastCancer. @OncoAlert.
2
68
203
Here the new algorithm to treat patients with advanced #HER2-positive #BreastCancer after #ESMO21 presidential session! Will we be finally able to cure some of them?? @myESMO @OncoAlert #bcsm
2
68
200
Finally out in @Annals_Oncology updated @ESOncology @myESMO International Consensus Guidelines for #BreastCancer in young women. looking forward to the sixth edition taking place online on October 8 !. #BCY5 @OncoAlert #bcsm @YSCBuzz @AnnPartridgeMD .
3
89
197
Finally out @myESMO guidelines on #fertility preservation and post-treatment #pregnancies in post-pubertal #cancer patients: extraordinary #oncofertility team effort !. @Annals_Oncology #OncoAlert #SurvOnc #UNIGE #UNIGEnonsiferma @UniGenova @SanMartino_Ge.
13
71
180
July 16, 2019. The best day of my life!!! Finally Agnese has joined our family!!!. A special acknowledgment to Dr. Anserini and Dr. @maclaudiaa for their work today at @SanMartino_Ge and for giving us the opportunity to live such emotions!!!. #TheBestDayEver #Daddy #Agnese
39
2
180
Looking forward to be on site in #Paris at #ESMO21 to finally "hug" again many friends after so long and to hear all the exciting news in the #BreastCancer field with several important practice changing data: I am sure it will be an unforgettable @myESMO event!. #Top10 @OncoAlert
8
61
170
More biomarkers are now needed to define the optimal #treatment algorithm for patients with advanced #HormoneReceptor-positive #BreastCancer . #SABCS20 #OncoAlert @OncoAlert #bcsm #BRCA #PIK3CA #ESR1
0
50
162
Presented at #SABCS22 results from #RIGHT trial on #ribociclib + endocrine therapy vs. chemotherapy as first-line therapy in metastatic aggressive HR+/HER2- #BreastCancer: very very important data to STOP using #chemotherapy in this setting !. @OncoAlert #bcsm @SABCSSanAntonio
7
49
163
Great discussion by dr Krop @Yale: here the new algorithm for the management of hormone receptor-positive/HER2-negative advanced #BreastCancer after #ASCO24 .@OncoAlert
1
61
162
Finally out in @NEJM updated results of #KEYNOTE522 showing improved event-free survival (& pCR) with #pembrolizumab added to standard #chemotherapy (including #carboplatin) in early TripleNegative #BreastCancer: historical moment!. @OncoAlert #bcsm #TNBC.
2
62
157
Two @NEJM articles this week showing worse survival outcomes with minimally invasive radical #hysterectomy as compared to #OpenSurgery among women with #CervicalCarcinoma: newer does not always mean better !
7
93
151
Honoured to have our IPD #metanalysis on the role of #GnRHa during #chemotherapy published in @JCO_ASCO; our #young #BreastCancer patients have now an available option to reduce the risk of developing chemotherapy-induced early #menopause and #infertility.
5
56
143
Here my selection of the top 10 #BreastCancer #abstracts to presented at the upcoming 2019 #ASCO Annual Meeting in #Chicago from May 31 to June 4: "Caring for Every #Patient, Learning from Every Patient" #ResearchSavesLives.#OncoAlert #bcsm @ASCO @OncoAlert @ASCOPost
7
54
148
So excited to share our results on #contraceptive use in #BreastCancer patients, a very important but neglected issue. super grateful to @dimeglio_anto @ines_vazluis @FAndreMD and all #CANTO investigators. @JAMANetworkOpen @JAMANetwork @OncoAlert . Link:
4
43
152
Out in @NEJM overall survival data from #KEYNOTE355 trial showing benefit of adding #pembrolizumab to chemotherapy as 1st-line treatment in advanced #PDL1+ triple-negative #BreastCancer: congrats super @JavierCortesMD @hoperugo et al!. @OncoAlert #bcsm.
5
58
151
Out in @Annals_Oncology updated EFS results of our metanalysis on neoadjuvant #platinum-based #chemotherapy for triple-negative #BreastCancer (6 RCTs, n=1,681): highly positive effect for addition of #carboplatin --> SoC in fit patients. @OncoAlert #bcsm.
3
65
147
Getting ready for an exciting @SABCSSanAntonio: here my #Top10 selection among the many expected important studies and my #Top5 abstracts on #BreastCancer in young women with an important contribution by our @UniGenova @SanMartino_Ge group!. @OncoAlert #UNIGEnonsiferma #bcsm #BCY
5
38
143
Looking forward to being finally in person again at #ASCO22: while preparing for the conference, I have selected my favorite #Top10 abstracts in #BreastCancer and #Top5 focused on young patients #BCY. major advances awaited!. @OncoAlert @ASCO @UniGenova @SanMartino_Ge @ASCOPost
0
47
144
After a long night shift, energy already fully recovered after finding in my mail box the @ConquerCancerFd Merit Award certificate: grateful to @ASCO for the chance to present our study on safety of #pregnancy in #BRCA-mut #BreastCancer patients #ASCO19 @SanMartino_Ge @UniGenova
21
8
147
Wow. what a masterpiece by @CristinaSaura3 and our @VHIO colleagues published in @AACR journal @CD_AACR showing that #ctDNA can be detected in breast milk. this has potential implications for #BreastCancer screening in young women. @OncoAlert #bcsm .
3
50
142
Finally the #ASCO21 abstracts are now available: here my selection of the #Top10 #BreastCancer abstracts & #Top5 specifically focused on young women #BCY. Link to the abstracts: @ASCO @OncoAlert @UniGenova @SanMartino_Ge #bcsm #UNIGEnonsiferma #OncoAlert
3
47
140
Someone is getting excited with the #ASCO21 plenary session (or is actually asking his dad to give her attention!)🙈🥰
7
3
139
Hope that our Italian #YoungOncologists perspective published in @myESMO journal @ESMO_Open can be helpful to #oncologists facing the challenges associated with #cancer care during #COVID19 outbreak. #OncoAlert @SanMartino_Ge @UniGenova @AIOMtweet. Link:
7
71
135
Very important week for endocrine sensitive HR+/#HER2- metastatic #BreastCancer: updated data from #MONALEESA2 (out in @NEJM) and #MONARCH3 showing consistent median overall survival exceeding 5 years with #ribociclib or #abemaciclib + ET.@OncoAlert #bcsm.
2
43
135
. finally at #ESMO21 median overall survival of patients with metastatic #HormoneReceptor-positive/#HER2-negative #BreastCancer is reported to exceed 5 years in a #RCT. still a lot of work to do for curing these patients but this is a very important result!.@OncoAlert @myESMO
2
38
134
Excited to see in @Nature_NPJ our #SABCS20 data on clinical behavior & outcomes of #BreastCancer in #young women with germline #BRCA mutations: huge academic effort & important step to improve the care of these patients. @OncoAlert #bcsm @SABCSSanAntonio.
3
36
129
Updated data from #monarchE trial just presented at #ESMOVirtualPlenary showing increased magnitude of benefit for the addition of #abemaciclib to adjuvant #EndocrineTherapy in high-risk HR+/HER2- #BreastCancer patients: very important data!. @myESMO @OncoAlert @Annals_Oncology
3
57
131
Expected to be presented at the #ASCO21 plenary session, #OlympiA trial is already published in @NEJM: impressive results with adjuvant #olaparib in #BRCA mutated #BreastCancer patients (8.8% absolute benefit in 3-y iDFS; HR 0.58). @ASCO @OncoAlert #bcsm.
1
39
122
Our study on pregnancy after #BreastCancer in young #BRCA carriers made it to the first @JAMA_current issue of 2024. what a great way to start the year!. @OncoAlert @UniGenova @SanMartino_Ge @AnnPartridgeMD @BlondeauxEva #bcsm . Link to the full article:
8
37
123
What a great slide to explain type I and type II errors !!! .#MCCRworkshop @BlondeauxEva @UniGenova @SanMartino_Ge @OncoAlert @EORTC @myESMO @AACR @ChiaraMolinelli @MartaPerachino
2
28
124
Ok. I’m not in #Berlin but this is pretty cool way of working from the beautiful countryside of #Genova in #Liguria, #Italy ! . And from where are you following #ESMOBreast20 ??. @myESMO #OncoAlert #congresswithmyfamily #lovemyjob @SanMartino_Ge @UniGenova #unigenonsiferma
16
7
122
Finally online in @NatureCancer phase II data showing the clinical activity of single agent #talazoparib in patients without germline #BRCA PVs but with other defects in homologous recombination genes like germline #PALB2 PVs.@OncoAlert #PARPi #bcsm. Link:
2
45
119
After a great #ESMObreastPreceptorship, time to celebrate my 36th #birthday with my special family. feel so lucky and grateful to have #Agnese and #Ruggero with us! .Thank you very much for all the birthday wishes I’ve received today!.@myESMO @OncoAlert @UniGenova @SanMartino_Ge
11
0
117
The most special day of the year has finally arrived…merry Christmas everyone!!! ❤️💝💙👨👩👧👦🎅🏻🎄 . @OncoAlert @UniGenova @SanMartino_Ge #UNIGEnonsiferma #genovamorethanthis
13
3
116
Great updated review article on #oncofertility just out in @CBCjournal by @MRazeti & @UniGenova @SanMartino_Ge team: hope it can help improving the counseling of young #BreastCancer patients. Free download for 50 days:. @OncoAlert #UNIGEnonsiferma #bcsm
5
44
117
Kindly share your opinion on our suggested algorithm (online in @SAGEPublishers journal #ClinMedInsightsOncol) for the current #adjuvant systemic treatment of #premenopausal early #BreastCancer patients. #OncoAlert #bcsm #BCY #UNIGEnonsiferma #UNIGE. Link:
4
72
112
General session 3 at #SABCS21: more data from #DESTINYBreast03 in patients with advanced #HER2+ #BreastCancer. my only comment is actually a request. from Monday morning onwards, please let me offer 2nd line #TrastuzumabDeruxtecan to all my patients. @OncoAlert #bcsm #TDXd
2
35
114
Honored and excited for this #award. always grateful to my super mentors @delmastro_lucia from @UniGenova @SanMartino_Ge and @E_de_Azambuja from @JulesBordet ! . @OncoAlert @MDPIOpenAccess @CurrentOncology #UNIGEnonsiferma #UNIGE #OspedaleSanMartino #ResearchSavesLives #Oncology.
🥇Congratulations to the winner of the CO 2021 Young Investigator Award:.Dr. Matteo Lambertini @matteolambe 👏👏.🗨️He is clearly a rising star in the field of clinical breast oncology. 👉 Thanks to all the nominators and nominees for their participation!
16
10
113
How to interpret the overall survival data with first-line CDK4/6 inhibitor plus endocrine therapy in HR+/HER2- advanced #BreastCancer ? And how to choose among the 3 available options ?. #ESMO22 @OncoAlert @myESMO #bcsm
1
37
113
Important study out in @NatureComms showing that postpartum #BreastCancer has a distinct molecular profile that may potentially explain the poorer outcomes of these patients: CDK4/6 inhibition and #immunotherapy to be implemented here.@OncoAlert #PPBC.Link
2
43
111
Updated data from #MONALEESA3 trial at median follow up of 70.8 months (!!) presented at #ESMObreast22: exciting to see another trial showing median #OS beyond 5 years in patients with metastatic endocrine sensitive HR+ #HER2- #BreastCancer receiving #ET + #ribociclib. @OncoAlert
0
35
110
In exactly one week from now! A big dream finally coming true: presenting in an educational session at @SABCSSanAntonio #SABCS22 with my super US mentor @AnnPartridgeMD from @DanaFarber! Looking forward to December 9, 3-5 pm San Antonio time 🥰🤩💪😎✌️.@OncoAlert #UNIGEnonsiferma
2
9
113
This is going to be a great and successful @myESMO annual conference for #BreastCancer (hoping to see you in person next year at #ESMO21): important science including results from 5 new RCTs expected to be presented at #ESMO20. #OncoAlert #ResearchSavesLives #StopCOVID19 #top10
5
48
109
Super proud of #ESMOYOC team and grateful to @DrJonLim for leading on such an important position paper on role and future of the clinician-scientist in #oncology, a key topic for many YOs.@ESMO_Open @myESMO @OncoAlert @AIOMtweet @TeresaSAmaral @UniGenova.
3
42
108
Published in @JAMAOnc @JAMANetwork 3-year survival data from the #ISPY trial: further evidence to support the strong prognostic value of achieving #pCR after #neoadjuvant therapy in early #BreastCancer regardless of subtype . #OncoAlert #bcsm @OncoAlert.
3
37
105
Great effort within @BIGagainstBC ALTTO trial led by super @ElisaAgostinett out in @Nature_NPJ showing that #PREDICT should not be used to give prognostic estimations to #HER2+ early #BreastCancer patients treated in the modern era. @OncoAlert #bcsm. Link:
2
32
101
Important start of 2023 with our #NeoALTTO gonadotoxicity analysis: weekly paclitaxel + #trastuzumab should not be considered completely gonadal safe. proper #oncofertility counseling is mandatory also in these women. @OncoAlert #bcsm #BreastCancer #HER2.
2
32
105
Looking forward to presenting today at #ASCO24 results of our BRCA BCY Collaboration providing evidence on clinical behavior of #BreastCancer in 4752 young #BRCA carriers according to specific BRCA gene and association of timing of genetic testing with prognosis. @OncoAlert #bcsm
2
30
106
Excellent overview about #BreastCancer biology by @PenaultLlorca at @myESMO preceptorship: #ER #PR and #HER2 are not enough anymore to guide treatment choice in the advanced setting. @OncoAlert @curijoey @E_de_Azambuja #esmopreceptorshipbc #ESMO #EducationIsKey #StopCOVID19 #bcsm
1
44
103
Looking forward to #ASCO21: important data by the Italian #BreastCancer group #GIM with the final analysis of #PROMISE-#GIM6 trial on #GnRHa use during #chemotherapy for ovarian function preservation. @OncoAlert #UNIGEnonsiferma #bcsm. Full abstract here:.
1
29
104
Very pragmatic algorithm proposed by the great @hoperugo to optimize the #neoadjuvant treatment of #TripleNegative #BreastCancer patients.#ESMO19 #OncoAlert
8
40
103
Great to be finally back to the soccer field with the @ASCO vs @myESMO game during #ASCO22: here the pre- and post-match pics 😝💪🔝🤩.@FAndreMD @ggabuin @M_Tagliamento @FiteniFrederic @dr_FPetracci @jo_ciccolini
9
10
102
Finally the day has arrived. just moved to our new apartment!!! First lunch, sunset view from our terrace and dinner that we will never forget!!! Grateful to all the people that have made this possible ❤️. #newlife #theThreeOfUs #Genova #Liguria #GenovaMoreThanThis #FamilyFirst
6
3
105
Happy 8-month anniversary to my princess Agnese. I will hug again my family after this #COVID19 nightmare will be under control. please help us and our #cancer patients to succeed in this battle. #StayAtHome #stateacasa #unitisivince #PrayForItaly #standwithitaly #FuckCOVID19
4
3
101
Our study on the safety of #pregnancy after #BreastCancer in #BRCA carriers is in the September issue of @ASCO_pubs #JCO.Final reference is: Journal of Clinical Oncology 38, no. 26, 3012-3023. #OncoAlert #ASCO19 #UNIGEnonsiferma @UniGenova @SanMartino_Ge .
3
29
102
And finally I have met the great @DrJNaidoo !!! .So exciting to work together in helping to build a super #ESMO24 program for next year @myESMO congress in #Barcelona…stay tuned !!! . @UniGenova @SanMartino_Ge #UNIGEnonsiferma
4
6
101
Ok let's be honest. I don't like virtual conferences that much. but this is probably the only opportunity to follow @myESMO Presidential Session with my two ladies wearing a @sampdoria t-shirt !!!.Looking forward to the adjuvant #abemaciclib data !. #ESMO20 #FamilyFirst #UNIGE
8
3
100
#ESMO19 Presidential Session abstract 3 - results from #KEYNOTE522: significant improvement in pCR and trend for event free survival with the addition of #pembrolizumab to neoadjuvant #chemotherapy in early #TripleNegative #BreastCancer.#bcsm #OncoAlert @OncoAlert @myESMO
0
53
99
General session 1 at #SABCS21: super discussion by the great @hoperugo on current knowledge and unmet needs about #immunotherapy for patients with #TripleNegative early and advanced #BreastCancer !. @OncoAlert #bcsm #IO #ImmOncol
0
45
97
This is my top 1 abstract on #BreastCancer in young women to be presented at #ASCO22 by my friend Dr. Kim from @AsanMedicalCtr: at more than 8-y median follow-up, addition of #OFS to #tam in #chemo pretreated patients increases DFS by absolute 5.2% (HR 0.67). congrats!.@OncoAlert
3
23
99
The most important trial presented at #SABCS22: at short-term follow-up, the #POSITIVE study shows that in selected young women with #BreastCancer a temporary interruption of #EndocrineTherapy for having a #pregnancy should be considered safe! .@OncoAlert @SABCSSanAntonio #bcsm
2
38
96
Extensive review on the state of the art in #BreastCancer treatment by the group of @DrEricWiner from @DanaFarber published in @JAMA_current: a huge progress has been made in the last decades but still a lot of work remains to be done #bcsm .
0
53
96
Updated results from the #ShortHER randomised trial comparing 9 weeks vs 1 year of adjuvant #trastuzumab in patients with #HER2+ early #BreastCancer presented at #ESMOBreast21 . @myESMO @OncoAlert #bcsm
0
32
98
Proud of @Shah_ONCO presenting at #ESMOAsia20 the results of an international survey investigating physicians' knowledge and attitudes on #fertility and #pregnancy issues in young #BreastCancer patients: thanks to @M_Tagliamento for the analyses!.@OncoAlert #UNIGEnonsiferma #bcsm
3
22
96
First meeting of the new #ESMOYOC: so proud to be part of this dream team & looking forward to many important projects for our young @myESMO members!. @franclongo @DrJonLim @EMariamidze @kfoury_maria @rillepihlak @pawel_sobczuk @Rodrosb @DrLizConnolly @DrHongchengZhu @kevinpunie
4
13
96
Eighth oral #BreastCancer abstract at #ASCO22: very important @NRGonc trial unfortunately showing no additional benefit of adding local treatment (#SBRT and/or surgery) to systemic therapy in patients with oligometastatic disease. @OncoAlert #bcsm @ASCO @Icro_Meattini
4
36
94
For those of you taking care of premenopausal #BreastCancer patients, this is our proposed algorithm for the adjuvant #EndocrineTherapy recently published in @JCO_ASCO: looking forward to knowing your opinion and practice in this setting .#OncoAlert #bcsm.
3
50
96
Finally super #DESTINYbreast03 data presented at #ESMO21 are out in @NEJM: #TrastuzumabDeruxtecan is the new standard 2nd line therapy in #HER2+ advanced #BreastCancer. congrats (and thanks) @JavierCortesMD et al for this terrific trial!. @OncoAlert #bcsm.
0
47
96
Really looking forward to having these data presented at #ESMO21 and published, happy to see that my practice of adding #carboplatin in all #TNBC patients fit for this regimen is a correct choice.@myESMO @OncoAlert #bcsm.Link to our @Annals_Oncology paper:.
2
29
95
Completely agree with this slide: local regional therapy in #BreastCancer patients with de novo stage IV disease should not be routinely used but it still has some role. and what about local treatment in oligometastatic disease?.#ASCO20 #PlenarySession #bcsm @OncoAlert
5
24
95
Final results from #EMBRACA trial online in @Annals_Oncology showing no overall survival benefit with #talazoparib versus #chemotherapy in patients with advanced #HER2-negative #BreastCancer and germline #BRCA pathogenic variants. #OncoAlert #bcsm @myESMO.
4
35
93
Sad news for #immunotherapy in #BreastCancer just before #ASCO19 with the phase 3 #KEYNOTE-119 trial: #pembrolizumab monotherapy is not superior to #chemotherapy in previously-treated patients with metastatic #TripleNegative disease #TNBC #OncoAlert #bcsm
8
65
92
Back together again!!!! Missed you so much!!!! If you apply to a @myESMO fellowship, it ends up that your mentor becomes one of you best friend. keep that in mind!!!! @E_de_Azambuja 🥰 #ESMO21 #ESMOYOC
2
5
96
In @NEJM a case report of severe immune-related enteritis after in utero exposure to #pembrolizumab: today at @ABCGlobalAll #ABC7 we discuss management of advanced #BreastCancer during #pregnancy reminding that #immunotherapy is contraindicated.@OncoAlert.
0
16
89
Feeling really thankful for what 2019 has brought to me: merry Christmas and happy new year to all of you and your families! . #familyreallymatters #familyfirst #AgneseLambertini #myfirstChristmas #thethreeofus #Christmas2019
9
2
90
---JOB OFFER---.I am hiring an early-stage researcher with expertise in cellular and molecular biology to join our #oncofertility team in #Genova.If interested, kindly send me an email to matteo.lambertini@unige.it.Thanks for sharing. @OncoAlert @UniGenova @SanMartino_Ge @AIRC_it.
0
43
89
. I will miss a lot to be in beautiful #Chicago this year and to see many friends. but it's so important that #cancer research is moving forward anyhow despite #COVID19: here my #top10list of #BreastCancer abstracts to be presented at #ASCO20.#OncoAlert #bcsm @DrSGraff @UniGenova
1
45
90
Extensive review on #immunotherapy for #cancer treatment during #pregnancy just out in @TheLancetOncol: crucial issue, so grateful for the chance to contribute!. Free download here:. @OncoAlert #UNIGEnonsiferma @UniGenova @SanMartino_Ge @HaanenJohn #IO
2
36
91
…I’m a bit confused here on prognostic & predictive value of #BreastCancer Index in premenopausal patients enrolled in #SOFT trial…need help from experts: results are the opposite than expected @SABCSSanAntonio #SABCS22 @OncoAlert @prat_aleix @c_sotiriou @DrHBurstein @LoiSher
6
21
89
Important RCT out in @Annals_Oncology showing non-inferiority of 5 vs. 7/10 days of G-CSF (#filgrastim) primary prophylaxis of #chemotherapy-induced febrile #neutropenia in early #BreastCancer: great editorial by @NicoleKuderer and @gary_lyman!.#OncoAlert.
3
32
90
Out in @ESMO_Open our review led by @puglisi_fabio's group on impact of #checkpoint inhibitors on #fertility #pregnancy and #SexualHealth: we need to do more considering the limited evidence despite the wide #immunotherapy use. @OncoAlert #UNIGEnonsiferma.
1
38
88
To all my @Twitter friends, #MerryChristmas and happy holidays to you and your families with the hope to hug again in 2021!. #Natale2020 #Christmas2020 #FamilyFirst #FamilyTime #TantiAuguri #Genova #GenovaMoreThanThis #MyPrincessAgnese #StopCOVID19 #MasksUp #vaccine #getTheShot
5
0
87
At the @myESMO presidential dinner with the best team ever ❤️ #ESMOYOC #ESMO23. @DrJonLim @EMariamidze @kfoury_maria @rillepihlak @PabloMando @DenizCanGuven1 @pawel_sobczuk @DrLizConnolly @Rodrosb @kevinpunie @ekocakavuk @DrHongchengZhu @mkmoutafi @OncoAlert
3
16
88
Finally back to the @ASCO annual meeting!!! So excited to be here!!! #ASCO22 🔥🎉🤟🔝💪 #UNIGEnonsiferma @UniGenova @SanMartino_Ge @OncoAlert
0
2
86
December 25, 2021. I have to admit that this is my favorite moment of the year and with the kids is really special again!. To all my @Twitter friends, merry #Christmas and happy #NewYear hoping to meet in person and hug each other soon!. Best from the Lambertini’s. @OncoAlert
4
3
89